Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesRetrospective Analysis of Long-term Lipid Apheresis at a Single Center
Therapeutic Apheresis and Dialysis, 11/05/09
Koziolek MJ et al. – Classical (diabetes mellitus, arterial hypertension, and smoking history), as well as novel risk factors (cGFR < 60 mL/min, statin withdrawal, mixed hyperlipoproteinemia, and elevated lipoprotein (a)) were associated with an elevated risk for MACE. All applied methods had comparable effects. All lipid apheresis methods proved to be safe and suitable for long–term treatment. The present data demonstrate that treatment with lipid apheresis is very effective and leads to long–term reduction in cardiovascular mortality and morbidity.
Related Articles
Total cholesterol and LDL levels decrease before rheumatoid arthritis
Annals of Rheumatic Diseases, 11/10/09
Relevance Score: 47%
Effects of lipid emulsions on lipid body formation and eicosanoid production by human peripheral blood mononuclear and polymorphonuclear cells
Clinical Nutrition, 10/15/09
Relevance Score: 47%
Long term effects on human plasma lipoproteins of a formulation enriched in butter milk polar lipid
Lipids in Health and Disease, 10/19/09
Relevance Score: 46%
Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels
Archives of Internal Medicine, 10/30/09
Relevance Score: 45%
Formulation, Stability, and Administration of Parenteral Nutrition With New Lipid Emulsions
Nutrition in Clinical Practice, 10/29/09
Relevance Score: 45%
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes
Journal of Hypertension, 11/25/09
The High Prevalence of Subclinical Atherosclerosis in Patients With Ankylosing Spondylitis Without Clinically Evident Cardiovascular Disease
Medicine, 11/20/09
Sponsor
Article Search
Sponsor
Sponsor